Mercator MedSystems Announces Receipt of NIH Grant for Research and Development of Local Anti-inflammatory Deep Vein Thrombosis Therapy
January 10, 2022, Emeryville, Calif. – Mercator MedSystems, Inc. (“Mercator” or the “company”), announced today that research has begun under a small business technology transfer (STTR) grant for approximately $300,000 funded by the National Institutes of...
Mercator Announces Enrollment of First Patient in DEXTERITY-AFP Clinical Trial Treating Inflammation in Deep Vein Thrombosis
EMERYVILLE, Calif., November 3, 2021 – Mercator MedSystems, Inc. (“Mercator”), a medical technology company specializing in localized drug therapy, today announced enrollment of the first patient in the DEXTERITY (DEXamethasone Therapy Examining Reduction of...
Updates and Conferences
Mercator Medsystems featured in BTIG’s Analyst Report: Medical Technology and Digital Health: Highlighting Private Companies Across the Medical Technology and Digital Health Landscape – Vol 18. March 2022 LINC 2022 – June 6 – June 9, 2022 Past Events American...
